Amphastar Pharmaceuticals (AMPH) Price to Earnings (2014 - 2026)

Amphastar Pharmaceuticals has reported Price to Earnings for 13 years, with the latest figure at 28.28 in Q2 2026.

• On a quarterly basis, Price to Earnings fell 17.78% year-over-year to 28.28 in Q2 2026; TTM through Jun 2026 was 10.29, a 18.51% increase from a year earlier, with the FY2025 full-year figure at 11.87, changed 0.4% from the prior year.
• Price to Earnings was 28.28 for Q2 2026 at Amphastar Pharmaceuticals, down from 136.2 in the prior quarter.
• The five-year high for Price to Earnings was 136.2 in Q1 2026, with the low at 28.28 in Q2 2026.
• Average Price to Earnings over 5 years is 66.54, with a median of 62.72 recorded in 2023.
• The largest YoY upside for Price to Earnings was 189.11% in 2022 against a maximum downside of 68.24% in 2022.
• Over 5 years, Price to Earnings stood at 46.08 in 2022, then surged by 93.3% to 89.07 in 2023, then retreated by 24.34% to 67.39 in 2024, then tumbled by 38.15% to 41.68 in 2025, then sank by 32.15% to 28.28 in 2026.
• The last three Price to Earnings figures came in at 28.28 (Q2 2026), 136.2 (Q1 2026), and 41.68 (Q4 2025), per Business Quant data.